179 related articles for article (PubMed ID: 15237448)
1. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
2. [Selective expansion of human natural killer cells].
Peng BG; Liang LJ; He Q; Li J; Lu MD
Ai Zheng; 2005 Oct; 24(10):1287-9. PubMed ID: 16219151
[TBL] [Abstract][Full Text] [Related]
3. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.
Harada H; Saijo K; Watanabe S; Tsuboi K; Nose T; Ishiwata I; Ohno T
Jpn J Cancer Res; 2002 Mar; 93(3):313-9. PubMed ID: 11927014
[TBL] [Abstract][Full Text] [Related]
4. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.
Harada H; Watanabe S; Saijo K; Ishiwata I; Ohno T
Exp Hematol; 2004 Jul; 32(7):614-21. PubMed ID: 15246157
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM
World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
7. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
8. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
[TBL] [Abstract][Full Text] [Related]
9. Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer.
Oikawa T; Kawai K; Ishiwata I; Ohno T; Akaza H
BJU Int; 2003 Dec; 92(9):1009-15. PubMed ID: 14632866
[TBL] [Abstract][Full Text] [Related]
10. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
13. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
[TBL] [Abstract][Full Text] [Related]
14. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
16. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
17. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of natural killer cells for clinical applications.
Klingemann HG; Martinson J
Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
[TBL] [Abstract][Full Text] [Related]
19. A GFP-transfected HFWT cell line, GHINK-1, as a novel target for non-RI activated natural killer cytotoxicity assay.
Harada H; Saijo K; Ishiwata I; Ohno T
Hum Cell; 2004 Mar; 17(1):43-8. PubMed ID: 15369136
[TBL] [Abstract][Full Text] [Related]
20. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
